Skip to main content
STVN logo

Stevanato Group S.p.A. (STVN) Stock: Price, Forecast & Analyst Target

Stevanato Group S.p.A. (STVN) — MoonshotScore 73/100 (Strong band), calculated Nov 18, 2026. Price $15.93 (+3.71%), as of the Nov 19, 2026 trading session; market cap $4.35B.

Educational signal · not a buy or sell recommendation · How to read this

$15.93 +$0.57 (+3.71%) Market Cap $4.35B

Stevanato Group S.p.A. · STVN · NYSE · Healthcare · Medical - Instruments & Supplies

Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors.

Price as of Nov 19, 2026

Key Statistics

73 of 100

MoonshotScore v2 · Stevanato Group S.p.A. (STVN)

Strong
Business Quality Solid (74)
Financial Safety Sound (63)
Valuation Full (59)
Growth Durability Compounding (89)
Momentum Quiet (49)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality and elite growth, but a full valuation. Business Quality: Solid; Financial Safety: Sound; Valuation: Full; Growth Durability: Compounding; Momentum: Quiet.

  • EPS beat 0 of the last 4 reports
  • Altman Z 3.63 · Piotroski F 5
  • ROE 9.3% · ROA 5.5% · current ratio 1.73

Helping: business quality, durable growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for STVN (52 recorded, newest six shown)
RecordedScoreBand
72Strong
69Strong
74Strong
74Strong
73Strong
73Strong

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$15.93
Change on the day+3.71%
52-week range$12.05–$24.01
Market capitalisation$4.35B—
Price / earnings (trailing)27.22
Shares traded on the day492.6K
Beta (volatility vs the S&P 500)0.8

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $13, high $26, latest $16. $26 $13 high $26 Oct 17, 2025 Nov 19, 2026 · $16 $24Oct 17, 2025$25Oct 31, 2025$22Nov 14, 2025$23Nov 28, 2025$21Dec 12, 2025$21Dec 26, 2025$21Jan 9, 2026$17Jan 23, 2026$16Feb 6, 2026$16Feb 20, 2026$15Mar 6, 2026$15Mar 20, 2026$14Apr 2, 2026$16Apr 17, 2026$18May 1, 2026$18May 15, 2026$19May 29, 2026$17Jun 12, 2026$18Jun 26, 2026$20Jul 10, 2026$20Jul 24, 2026$20Aug 7, 2026$23Aug 21, 2026$21Sep 4, 2026$22Sep 18, 2026$20Oct 2, 2026$19Oct 16, 2026$19Oct 30, 2026$16Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Stevanato Group S.p.A. (STVN): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Moderate
Valuation Neutral
Growth Durability Strong
Momentum Neutral

Legends Council

3 lenses, 3 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Griffin-style lens (simulated) Ken Griffin Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 19, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Neutral
Debt/Equity Moderate
ROE Neutral
Gross Margin Neutral

Read on: Nov 19, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company less favourably than the MoonshotScore does: Klarman-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Stevanato Group S.p.A. (STVN), and what does it report?

Short answer

Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. Stevanato Group S.p.A. (STVN) is listed on NYSE. Healthcare / Medical Instruments & Supplies SEC filing business address: Piombino Dese (PD) VIA Molinella, 17, Padua, 35017. It employs 6,010 people and is led by Franco Stevanato. The market values it at $4.35B.

2 · Latest results

What do the latest results show for Stevanato Group S.p.A. (STVN)?

Short answer · as of

Against analyst estimates the company has EPS beat 0 of the last 4 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025€303M€36M€0.13 (diluted)
Dec 2025€346M€48M€0.17 (diluted)
Mar 2026€274M€28M€0.10 (diluted)
Jun 2026€302M€23M€0.08 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Stevanato Group S.p.A. (STVN)?

Short answer · as of

The MoonshotScore pillars rate business quality, durable growth as strengths. The distress and quality screens read Altman Z 3.63 · Piotroski F 5. Trailing ratios: ROE 9.3% · ROA 5.5% · current ratio 1.73.

Data-derived red flags

  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
  • Rich valuation — a P/E of 27.22 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
4 · What to check next?

What should you watch next at Stevanato Group S.p.A. (STVN)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $1.25B · EPS 0.60 · 10 analysts. Current published price targets run low $17.50 · high $32.00 · consensus $24.50 · median $24.00 against a quoted price of $15.93 (as of Nov 19, 2026).

What the records here don't tell us

  • Detailed statement figures are not shown because their conversion to USD has not been verified.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Stevanato Group S.p.A. compare with its peers?

Short answer

Stevanato Group S.p.A.'s score ranks tied for 6th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Research dated 2026-09-13.

Stevanato is a consolidated supplier of critical pharma manufacturing infrastructure, a position earned through manufacturing excellence and regulatory relationships. The company is not a low-cost commodity manufacturer—it competes on quality, compliance, and integrated solutions (vials plus delivery systems plus processing equipment from a single vendor). This integrated model is different from pure vial manufacturers or pure equipment builders.

Compared to peer equipment makers (Bausch + Lomb parent Bausch Health competitors), Stevanato is more exposed to consumable demand cycles. Compared to pure vial suppliers, Stevanato has scale advantages and integrated offerings. Compared to contract manufacturers, Stevanato is upstream in the supply chain, insulated from formulation risk. The real peer set is large-cap pharma suppliers like Sartorius or Getinge, all facing shared cycles around pharma capital spending and biotech activity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
AtriCure, Inc. (ATRC) Same industry, near in market value$55.45 Nov 18, 2026$2.82B95 5-pillar Nov 18, 2026
BrightSpring Health Services, Inc. (BTSG) Named competitor$64.02 Nov 19, 2026$12.7B87 5-pillar Nov 18, 2026
Haemonetics Corporation (HAE) Same industry, near in market value$120.37 Nov 19, 2026$5.48B83 5-pillar Nov 18, 2026
Merit Medical Systems, Inc. (MMSI) Same industry, near in market value$84.41 Nov 19, 2026$5.06B81 5-pillar Nov 18, 2026
AptarGroup, Inc. (ATR) Named competitor$140.34 Nov 19, 2026$8.90B77 5-pillar Nov 18, 2026
Stevanato Group S.p.A. (STVN) — this page$15.93$4.35B73
ICU Medical, Inc. (ICUI) Same industry, near in market value$175.76 Nov 19, 2026$4.40B73 5-pillar Nov 18, 2026
Avantor, Inc. (AVTR) Same industry, near in market value$15.12 Nov 19, 2026$10.3B71 5-pillar Nov 18, 2026
Azenta, Inc. (AZTA) Same industry, near in market value$47.09 Nov 19, 2026$1.97B64 5-pillar Nov 18, 2026
Warby Parker Inc. (WRBY) Same industry, near in market value$24.13 Nov 19, 2026$3.00B62 5-pillar Nov 18, 2026
Teleflex Incorporated (TFX) Same industry, near in market value$163.40 Nov 19, 2026$6.48B61 5-pillar Nov 18, 2026
Bausch + Lomb Corporation (BLCO) Same industry, near in market value$20.95 Nov 18, 2026$7.49B35 5-pillar Nov 18, 2026
Axsome Therapeutics, Inc. (AXSM) Named competitor$135.68 Nov 19, 2026$7.14B34 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$17.50 – $32.00
Consensus target
$24.50
Median target
$24.00
Revenue estimate
$1.25B
EPS estimate
$0.60

Consensus record · Captured .

Measured against a quoted price of $15.93 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 9, 2026

Transactions
27
Identified insiders
9
Purchases
2
Sales
8
Other transactions
17

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held STVN in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported STVN in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Stevanato Group S.p.A. (STVN)?

Read these with our analysis →

What Investors Ask About Stevanato Group S.p.A. (STVN) — Healthcare

These answers are editorial: 1 of these 9 answers is drawn from the STVN research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for STVN?

STVN carries the MoonshotScore stated above — the Strong band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Stevanato Group S.p.A. provides integrated solutions for the pharmaceutical and healthcare industries.

Is STVN a good stock to buy?

Stock Expert AI does not rate STVN buy, sell or hold. Stevanato Group S.p.A. carries a MoonshotScore, in the Strong band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the STVN stock price today?

The last price recorded for Stevanato Group S.p.A. (STVN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the STVN price target?

The analyst consensus price target for Stevanato Group S.p.A. (STVN), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the main risks for STVN?

Stevanato Group S.p.A. faces several risks inherent to the medical instruments and supplies industry. Economic downturns and reduced healthcare spending could negatively impact demand for its products and services.

What are the key factors to evaluate for STVN?

Stevanato Group S.p.A. (STVN) holds a MoonshotScore in the high range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. By establishing a presence in these markets, Stevanato Group can tap into new customer bases and diversify its revenue streams. Not financial advice.

How frequently does STVN data refresh on this page?

STVN's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven STVN's recent stock price performance?

Stevanato Group S.p.A. (STVN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong market position in the pharmaceutical and healthcare industries. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider STVN overvalued or undervalued right now?

The trailing P/E of Stevanato Group S.p.A. (STVN) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 26 figures on this page — 1 from SEC filings and earnings calls, 18 from Financial Modeling Prep (FMP), 5 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • 5. How does Stevanato Group S.p.A. compare with its peers?: Business description; Trailing twelve-month ratio set; Analyst revenue and earnings estimates (average)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.